GlassScriptPhysician profile
Ramkrishna R Kothur
NPI 1922113075
$5,804.55
in general payments reported to CMS, 2019-2025
42 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $83.11 · 2021: $276 · 2022: $911 · 2023: $1,243 · 2024: $1,420 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.83 |
| Education | $110.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.69 | 2019-2025 | |
| Genzyme Corporation | $652.47 | 2022-2025 | |
| Janssen Biotech, INC. | $642.28 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $619.39 | 2019-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $367.05 | 2021-2023 | Zeposia |
| Celgene Corporation | $266.10 | 2022-2024 | Zeposia |
| Pfizer INC. | $189.50 | 2023-2025 | |
| Ardelyx, INC. | $137.18 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $135.57 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.05 | 2019-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $121.83 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $112.32 | 2019-2024 | Dificid |
| Lilly USA, LLC | $109.72 | 2023-2025 | Omvoh |
| Organon LLC | $82.59 | 2022-2025 | Hadlima, Renflexis |
| Regeneron Healthcare Solutions, INC. | $79.54 | 2023-2024 | Dupixent |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramkrishna Kothur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.